Immutep Reports Positive Interim Phase I Data for Autoimmune Candidate IMP761
IMMP sits 32% above its 52-week low of $0.293 on light trading volume (0.1× avg).
Summary
Immutep announced positive interim Phase I data for its autoimmune candidate IMP761, showing favorable safety and statistically significant activity, providing a key positive development after recent clinical setbacks.
Key Events · Product Development and Regulatory · IMMP
-
Positive Phase I Results
IMP761 met its primary endpoint, demonstrating favorable safety and tolerability in healthy volunteers during the single ascending dose part of the study.
-
Statistically Significant Activity
Phase I data showed statistically significant pharmacodynamic activity at 7 mg/kg, supporting further clinical investigation in autoimmune diseases.
-
Potential for Autoimmune Treatment
IMP761, a first-in-class LAG-3 agonist, demonstrated clear immunosuppressive effects, positioning it for multiple T-cell mediated autoimmune indications.
-
Strategic Importance
This positive development for a pipeline candidate in autoimmune diseases helps diversify the company's prospects following the recent discontinuation of its lead cancer trial.
Analysis · IMMP · Life Sciences
This filing provides crucial positive clinical data for IMP761, a LAG-3 agonist antibody for autoimmune diseases. The successful Phase I results, demonstrating favorable safety and statistically significant pharmacodynamic activity, offer a much-needed positive development for Immutep following the recent discontinuation of its lead cancer trial (TACTI-004). This data supports further clinical development and potential strategic partnerships, which are vital for the company's pipeline diversification and future.
At the time of this filing, IMMP was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.6M. The 52-week trading range was $0.29 to $3.53. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.